Results 211 to 220 of about 7,263 (276)

Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT₃ Antagonist Antiemetic Drugs. [PDF]

J Clin Pharmacol
Thompson LE, Ghimire A, Wen X, Kim C, Doherty CL, Buckley BT, Bowles DW, O'Bryant CL, Jaimes EA, Aleksunes LM, Joy MS.   +10 more
europepmc   +1 more source

Effects of motion sickness patch on postoperative nausea and vomiting in female patients undergoing thyroid surgery: a randomized clinical trial. [PDF]

Int J Surg
Yu TT, Han LH, Zhao JH, Fu JJ, Fang PP, Lu Y.   +5 more
europepmc   +1 more source

Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy. [PDF]

J Oncol Pharm Pract
Araz M, Beypinar I, Inci F, Koral L, Kocak MZ, Korkmaz M, Demirkiran A, Eryilmaz MK, Artac M.   +8 more
europepmc   +1 more source

Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy

, 2018
Snežana Bošnjak, Ljiljana Stamatović, Maria Elisa Borroni, Giada Rizzi, Karin Jordan   +4 more
openalex   +1 more source

Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates. [PDF]

Future Oncol
Park YH, Bianchini G, Cortés J, Licata L, Vidal M, Iihara H, Roeland EJ, Jordan K, Scotté F, Schwartzberg L, Navari RM, Aapro M, Rugo HS.   +12 more
europepmc   +1 more source

Guidance on the short hydration method for cisplatin administration. [PDF]

Int J Clin Oncol
Ninomiya K, Kunimasa K, Kurata Y, Sato Y, Fujisaka Y, Ishikawa H, Hotta K.   +6 more
europepmc   +1 more source

Antiemetic medications for preventing chemotherapy-induced nausea and vomiting in children: a systematic review and Bayesian network meta-analysis. [PDF]

Support Care Cancer
Walker R, Dias S, Phillips RS.
europepmc   +1 more source

A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study. [PDF]

Int J Clin Oncol
Aoyama T, Ooki A, Oba K, Nishikawa K, Kawabata R, Honda M, Maeda H, Kanda M, Sugiyama K, Makiyama A, Segami K, Takahashi M, Shindo Y, Namikawa T, Oshima T, Katayama A, Shiosakai K, Sakamoto J.   +17 more
europepmc   +1 more source

Evaluation of the Efficacy and Safety of Palonosetron + Dexamethasone (1-day) + Fosaprepitant + Olanzapine (2.5 mg) in Patients with Lung Cancer Undergoing Carboplatin-based Chemotherapy

Yuki Mikame, Yasunari Okuda, Makoto Shinada, Takahiro Saito, Naoto Kobayashi, Takefumi Yamashita, Masato Nakata, Daichi Arai, Mika Ohira, Itoe TAMURA, Yasushi Imai   +10 more
openalex   +2 more sources